Gastro-oesophageal reflux disease is one of the most prevalent gastrointestinal conditions, affecting approximately 20% of Western populations and causing chronic heartburn, regurgitation, and oesophageal complications including Barrett's oesophagus. Proton pump inhibitors remain the pharmacological standard; refractory disease may require antireflux surgery or endoscopic procedures. Novel potassium-competitive acid blockers offer faster symptom relief and alternative options for PPI-intolerant patients.
Loading articles...
